References
- Hockel M, Schlenger K, Hockel S, . Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 1999;59:4525–4528.
- Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93: 266–276.
- Semenza GL. Intratumoral hypoxia, radiation resistance, and HIF-1. Cancer Cell 2004;5:405–406.
- Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721–732.
- Rohwer N, Cramer T. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Update 2011;14:191–201.
- Greenberg P, Cox C, LeBeau MM, . International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079–2088.
- Tong H, Hu C, Zhuang Z, . Hypoxia-inducible factor-1α expression indicates poor prognosis in myelodysplastic syndromes. Leuk Lymphoma 2012;53:2412–2418.
- Isaacs JS, Jung YJ, Mimnaugh EG, . Hsp90 regulates a Von Hippel-Lindau independent hypoxia-inducible factor- 1alpha-degradative pathway. J Biol Chem 2002;277:29936–29944.
- Mabjeesh NJ, Escuin D, LaVallee TM, . 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003;3:363–375.